STOCK TITAN
  1. Home
  2. Sec-filings
  3. ARTL
  4. [8-K] ARTELO BIOSCIENCES, INC. Reports Material Event

Artelo Biosciences (Nasdaq: ARTL) to trade post-split Aug 31

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Artelo Biosciences, Inc. (ARTL) approved a 1-for-9 reverse stock split of its common stock. The common stock is expected to begin trading on a split-adjusted basis on August 31, 2026 on the Nasdaq Capital Market.

Every nine shares of issued and outstanding common stock will be automatically combined into one share, with no fractional shares issued; holders otherwise entitled to a fraction will receive one whole share. The company states that each shareholder’s pro-rata ownership will remain unchanged, and all outstanding warrants and other derivatives will automatically adjust to reflect the reverse split. Immediately after effectiveness, there will be approximately 547,774 shares of common stock issued and outstanding.

Positive

  • None.

Negative

  • None.

Filing Explained

The company says the 1-for-9 reverse split is intended to raise the per-share price and improve marketability and liquidity; the split itself does not change the company’s value.

Reverse stock split ratio 1-for-9 reverse stock split Each nine shares of issued and outstanding common stock will be combined into one share
Split-adjusted trading start date August 31, 2026 Common stock expected to begin trading on a split-adjusted basis on this date
Post-split shares outstanding approximately 547,774 shares of Common Stock Immediately after the reverse stock split becomes effective
New CUSIP for Common Stock 04301G805 CUSIP number for the common stock following the reverse stock split
reverse stock split financial
"today announced a 1-for-9 reverse stock split"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
split-adjusted basis financial
"will begin trading on a split-adjusted basis on the Nasdaq Capital Market"
An adjustment to historical share prices and share counts that reflects past stock splits or reverse splits so that old data lines up with the current number of shares. Think of it like resizing an old photograph so it matches a new frame: it keeps price charts, returns and per‑share metrics comparable over time, which matters to investors who need accurate performance, valuation and trend analysis.
fractional shares financial
"No fractional shares will be issued as a result of the Reverse Split"
Fractional shares are portions of a whole share of a stock or fund, allowing investors to own less than one full unit. They make it possible to invest a specific dollar amount rather than buy whole shares, like buying a slice of a pizza instead of the entire pie. For investors this lowers the cost barrier, helps with diversification, and lets you reinvest dividends or purchase expensive stocks in small, precise amounts.
warrants financial
"current outstanding warrants to purchase shares of Common Stock and other derivatives"
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
lipid-signaling pathways medical
"therapeutics that modulate lipid-signaling pathways, with a diversified pipeline"
Lipid-signaling pathways are networks of biochemical messages that use fat-like molecules to tell cells when to grow, move, inflame, or die—think of them as a phone and wiring system inside the body that routes instructions using specific fat-based messengers. Investors care because drugs or tests that modify these pathways can become treatments or biomarkers for major diseases, affecting regulatory approval, market size and company valuation when a therapy successfully changes how those cellular messages behave.

FAQ

What reverse stock split did ARTL announce?
Artelo Biosciences announced a 1-for-9 reverse stock split of its common stock, in which every nine existing shares will be automatically combined into one share. The company states the split is intended to increase the per-share price to improve marketability and liquidity.

When will ARTL start trading on a split-adjusted basis?
Artelo Biosciences expects its common stock to begin trading on a split-adjusted basis on August 31, 2026 on the Nasdaq Capital Market, following the effectiveness of the 1-for-9 reverse stock split.

How does the ARTL reverse split affect fractional shares?
No fractional shares will be issued. Stockholders who otherwise would be entitled to a fractional share after the 1-for-9 reverse split will automatically be entitled to receive one whole share of common stock for each such fractional share.

How many ARTL shares will be outstanding after the reverse split?
Immediately after the reverse stock split becomes effective, Artelo Biosciences states there will be approximately 547,774 shares of common stock issued and outstanding.

Will ARTL shareholders’ ownership percentage change after the reverse split?
Artelo Biosciences states that each shareholder’s pro-rata percentage ownership will remain unchanged as a result of the 1-for-9 reverse stock split, and that no further action is required by shareholders.

What happens to ARTL warrants and other derivatives in the reverse split?
The company states that all current outstanding warrants to purchase shares of common stock and other derivatives will automatically adjust per their terms to reflect the 1-for-9 reverse stock split.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →

EXHIBIT 99.1

 

 

Artelo Biosciences Announces Reverse Stock Split

 

Shares Expected to Begin Trading on a Split-Adjusted Basis on August 31, 2026

 

SOLANA BEACH, CA – August 27, 2026 – Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today announced a 1-for-9 reverse stock split (“Reverse Split”) of the Company’s common stock (“Common Stock”). The Company’s Common Stock will begin trading on a split-adjusted basis on the Nasdaq Capital Market commencing at the market open on August 31, 2026. The Reverse Split is being effected in order to increase the price per share of the Common Stock to improve its marketability and liquidity. The new CUSIP number for the Common Stock following the Reverse Split will be 04301G805.

 

As a result of the Reverse Split, each nine shares of the Company’s issued and outstanding Common Stock will be automatically combined and converted into one issued and outstanding share of Common Stock. No fractional shares will be issued as a result of the Reverse Split. Stockholders who otherwise would be entitled to a fractional share will automatically be entitled to receive one whole share of Common Stock for each such fractional share. Each shareholder’s pro-rata percentage ownership will remain unchanged as a result of the Reverse Split and no further action is required by shareholders. All of the Company’s current outstanding warrants to purchase shares of Common Stock and other derivatives automatically adjust per their terms to reflect the Reverse Split. Immediately after the Reverse Split becomes effective, there will be approximately 547,774 shares of Common Stock issued and outstanding. For further details, all shareholders are invited to review the Current Report on Form 8-K regarding the Reverse Split which will be filed August 27, 2026.

 

About Artelo Biosciences

 

Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways, with a diversified pipeline addressing significant unmet needs in anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Led by an experienced executive team collaborating with world-class researchers and technology partners, Artelo applies rigorous scientific, regulatory, and commercial expertise to maximize stakeholder value. More information is available at www.artelobio.com and X: @ArteloBio.

 

Forward-Looking Statements

 

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws.

 

Investor Relations Contact:

 

Crescendo Communications, LLC

Tel: 212-671-1020

Email: ARTL@crescendo-ir.com

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

7 documents

Press Releases

Other Documents